270 related articles for article (PubMed ID: 31819179)
1. Targeting aerobic glycolysis by dichloroacetate improves Newcastle disease virus-mediated viro-immunotherapy in hepatocellular carcinoma.
Meng G; Li B; Chen A; Zheng M; Xu T; Zhang H; Dong J; Wu J; Yu D; Wei J
Br J Cancer; 2020 Jan; 122(1):111-120. PubMed ID: 31819179
[TBL] [Abstract][Full Text] [Related]
2. Fludarabine as an Adjuvant Improves Newcastle Disease Virus-Mediated Antitumor Immunity in Hepatocellular Carcinoma.
Meng G; Fei Z; Fang M; Li B; Chen A; Xu C; Xia M; Yu D; Wei J
Mol Ther Oncolytics; 2019 Jun; 13():22-34. PubMed ID: 31011625
[TBL] [Abstract][Full Text] [Related]
3. Dichloroacetate blocks aerobic glycolytic adaptation to attenuated measles virus and promotes viral replication leading to enhanced oncolysis in glioblastoma.
Li C; Meng G; Su L; Chen A; Xia M; Xu C; Yu D; Jiang A; Wei J
Oncotarget; 2015 Jan; 6(3):1544-55. PubMed ID: 25575816
[TBL] [Abstract][Full Text] [Related]
4. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic measles virus enhances antitumour responses of adoptive CD8
Chen A; Zhang Y; Meng G; Jiang D; Zhang H; Zheng M; Xia M; Jiang A; Wu J; Beltinger C; Wei J
Sci Rep; 2017 Jul; 7(1):5170. PubMed ID: 28701757
[TBL] [Abstract][Full Text] [Related]
6. Recombinant adenovirus expressing the fusion protein PD1PVR improves CD8
Zhang H; Zhang Y; Dong J; Zuo S; Meng G; Wu J; Wei J
Cell Oncol (Dordr); 2021 Dec; 44(6):1243-1255. PubMed ID: 34491549
[TBL] [Abstract][Full Text] [Related]
7. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
Vijayakumar G; Palese P; Goff PH
EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
[TBL] [Abstract][Full Text] [Related]
9. Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma.
Shen YC; Ou DL; Hsu C; Lin KL; Chang CY; Lin CY; Liu SH; Cheng AL
Br J Cancer; 2013 Jan; 108(1):72-81. PubMed ID: 23257894
[TBL] [Abstract][Full Text] [Related]
10. Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1.
Kim TS; Lee M; Park M; Kim SY; Shim MS; Lee CY; Choi DH; Cho Y
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576192
[TBL] [Abstract][Full Text] [Related]
11. Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy.
Bai FL; Yu YH; Tian H; Ren GP; Wang H; Zhou B; Han XH; Yu QZ; Li DS
Cancer Biol Ther; 2014 Sep; 15(9):1226-38. PubMed ID: 24971746
[TBL] [Abstract][Full Text] [Related]
12. Combination Immunotherapy of Oncolytic Flu-Vectored Virus and Programmed Cell Death 1 Blockade Enhances Antitumor Activity in Hepatocellular Carcinoma.
Yu H; Sun F; Xu Y; Yang H; Tian C; Li C; Kang Y; Hao L; Yang P
Hum Gene Ther; 2024 Mar; 35(5-6):177-191. PubMed ID: 38386514
[TBL] [Abstract][Full Text] [Related]
13. An oncolytic adenovirus delivering TSLC1 inhibits Wnt signaling pathway and tumor growth in SMMC-7721 xenograft mice model.
Wang Y; Huang P; Hu Y; Guo K; Jia X; Huang B; Liu X; He X; Huang F
Acta Biochim Biophys Sin (Shanghai); 2021 May; 53(6):766-774. PubMed ID: 33928346
[TBL] [Abstract][Full Text] [Related]
14. Dichloroacetate enhances adriamycin-induced hepatoma cell toxicity in vitro and in vivo by increasing reactive oxygen species levels.
Dai Y; Xiong X; Huang G; Liu J; Sheng S; Wang H; Qin W
PLoS One; 2014; 9(4):e92962. PubMed ID: 24728083
[TBL] [Abstract][Full Text] [Related]
15. Newcastle disease virus: a promising agent for tumour immunotherapy.
Zhao L; Liu H
Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):725-30. PubMed ID: 22211810
[TBL] [Abstract][Full Text] [Related]
16. A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma.
Wang Y; Liu T; Huang P; Zhao H; Zhang R; Ma B; Chen K; Huang F; Zhou X; Cui C; Liu X
Oncotarget; 2015 May; 6(15):13564-78. PubMed ID: 25980438
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic Newcastle disease virus delivered by Mesenchymal stem cells-engineered system enhances the therapeutic effects altering tumor microenvironment.
Keshavarz M; Ebrahimzadeh MS; Miri SM; Dianat-Moghadam H; Ghorbanhosseini SS; Mohebbi SR; Keyvani H; Ghaemi A
Virol J; 2020 May; 17(1):64. PubMed ID: 32370750
[TBL] [Abstract][Full Text] [Related]
18. Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model.
El-Shemi AG; Ashshi AM; Na Y; Li Y; Basalamah M; Al-Allaf FA; Oh E; Jung BK; Yun CO
J Exp Clin Cancer Res; 2016 May; 35():74. PubMed ID: 27154307
[TBL] [Abstract][Full Text] [Related]
19. Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy.
Schirrmacher V; van Gool S; Stuecker W
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361831
[TBL] [Abstract][Full Text] [Related]
20. Targeting STAT3 enhances NDV-induced immunogenic cell death in prostate cancer cells.
Wang X; Shao X; Gu L; Jiang K; Wang S; Chen J; Fang J; Guo X; Yuan M; Shi J; Ding C; Meng S; Xu Q
J Cell Mol Med; 2020 Apr; 24(7):4286-4297. PubMed ID: 32100392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
